Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Kahler Disease

rosiglitazone has been researched along with Kahler Disease in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fu, J; Huang, H; Huang, Z; Liu, R; Liu, Y; Rui, M; Wang, Z1
Fu, J; Fu, T; Huang, H; Liu, Y; Rui, M1
Chen, G; Fu, J; Huang, H; Wu, D1
Chang, W; Chen, G; Chow, HC; Fu, J; Huang, H; Leung, AY; Liang, R; Wu, D1
Chang, HR; Chen, GH; Chow, HC; Huang, HW; Leung, AY; Liang, R; Wu, DP2
Chen, P; Chow, HC; Fan, YY; Fu, JX; Huang, HW; Leung, AY; Li, BZ; Li, J; Liang, R; Liu, R; Zhang, H; Zhang, XH1
Bängeroth, K; Elstner, E; Eucker, J; Heider, U; Jakob, C; Krebbel, H; Possinger, K; Sezer, O; Zang, C; Zavrski, I1

Other Studies

8 other study(ies) available for rosiglitazone and Kahler Disease

ArticleYear
Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia-inducible factor-1α and insulin-like growth factor-1 mRNA expression.
    Molecular medicine reports, 2014, Volume: 10, Issue:4

    Topics: Cell Proliferation; Cell Survival; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Humans; Hypoglycemic Agents; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Multiple Myeloma; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Cells, Cultured

2014
[Effect of rosiglitazone on the expression of HIF1α and IGF1 mRNA in myeloma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:7

    Topics: Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Multiple Myeloma; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; RNA, Messenger; Rosiglitazone; Thiazolidinediones

2014
Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:6

    Topics: Aged; Animals; Antineoplastic Agents; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Shape; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Immunoglobulin Light Chains; Integrin alpha5; Male; Middle Aged; Multiple Myeloma; PPAR gamma; Rosiglitazone; Syndecan-1; Thiazolidinediones; Tretinoin; Tumor Cells, Cultured

2009
All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
    European journal of haematology, 2009, Volume: 83, Issue:3

    Topics: Aged; Apoptosis; Caspase 3; Cell Differentiation; Cell Line, Tumor; Cell Survival; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Multiple Myeloma; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tretinoin

2009
[Rosiglitazone and all-trans retinoic acid inhibit human myeloma cell proliferation via apoptosis signaling pathway modulation].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tretinoin

2009
[Differentiating effect of PPARgamma ligand rosiglitazone and all trans-retinoic acid on myeloma cells and its possible mechanism].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:12

    Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Drug Synergism; Humans; Integrin alpha5; Intracellular Signaling Peptides and Proteins; Multiple Myeloma; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tretinoin; Up-Regulation

2009
[Influence of rosiglitazone and all-trans-retinoic acid on angiogenesis and growth of myeloma xenograft in nude mice].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:9

    Topics: Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Multiple Myeloma; Neoplasm Transplantation; Neovascularization, Pathologic; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tretinoin; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2012
Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma.
    Anti-cancer drugs, 2004, Volume: 15, Issue:10

    Topics: Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Humans; Ligands; Multiple Myeloma; Pioglitazone; PPAR gamma; Prostaglandin D2; Rosiglitazone; Thiazolidinediones

2004